Ramzia I. El-Bagary, Ehab F. Elkady, Bassam M. Ayoub

Similar documents
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt;

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method

Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

Impact factor: 3.958/ICV: 4.10 ISSN:

Available online at Universal Research Publications. All rights reserved

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

J Pharm Sci Bioscientific Res (4): ISSN NO

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Journal of Chemical and Pharmaceutical Research, 2017, 9(3): Research Article

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

Research Article Available online at

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

Department of Quality Assurance, Luqman College of Pharmacy, GULBARGA (K.S.) INDIA ABSTRACT

Research Article. Figure 1. Chemical structure of doxofylline. Indonesian J. Pharm. Vol. 24 No. 1 : ISSN-p :

Volume 6, Issue 2, January February 2011; Article-015

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Scholars Research Library. Rapid and sensitive RP-HPLC analytical method development and validation of Pioglitazone hydrochloride

STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG AND IT S PHARMACEUTICAL DOSAGE FORM

Validated First Order Derivative Spectroscopic Method for the determination of Stavudine in Bulk and Pharmaceutical Dosage Forms

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Stability Indicating RP-HPLC Method for Determination of Valsartan in Pure and Pharmaceutical Formulation

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE ESTIMATION OF NICERGOLINE IN MARKETED FORMULATIONS

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF GABAPENTIN IN PURE AND PHARMACEUTICAL FORMULATIONS

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

VALIDATION STUDY OF THE HPLC ASSAY OF SOME ANTIAMOEBIC AGENTS

B. Anupama et al. IRJP 2 (1)

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS.

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir

SIMULTANEOUS ESTIMATION OF MEFENAMIC ACID AND PARACETAMOL IN SUSPENSION FORM BY USING UPLC

Pharmacophore 2011, Vol. 2 (4), ISSN Pharmacophore. (An International Research Journal)

Simultaneous estimation of meclizine and nicotinic acid by using RP-HPLC

DEVELOPMENT AND VALIDATION OF A RP-HPLC METHOD FOR DETERMINATION OF LOPINAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM

RP-HPLC Estimation of Trospium Chloride in Tablet Dosage Forms

Department of Chemistry, JNTUACE, Kalikiri

INDICATING LIQUID CHROMATOGRAPHIC METHOD FOR QUANTIFICATION OF CIPROFLOXACIN HCL, ITS RELEATED SUBSTANCE AND TINIDAZOLE IN TABLET DOSAGE FORM

International Journal of Pharma and Bio Sciences V1(1)2010. HPLC method for analysis of Lercanidipine Hydrochloride in Tablets

Chapter 4: Verification of compendial methods

DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN PLASMA AND FORMULATION

Journal of Drug Delivery and Therapeutics

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

Simultaneous estimation of ramipril and valsartan by RP-HPLC method in combined. dosage form

Determination of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form By Reverse Phase High Performance Liquid Chromatography Method

SIMPLE AND SENSITIVE VALIDATED REVERSE PHASE HPLC-UV METHOD FOR THE DETERMINATION OF LYMECYCLINE IN PHARMACEUTICAL DOSAGE FORMS

Pelagia Research Library

INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES

Development and Validation of Sensitive RP-HPLC Method for the Estimation of Glibenclamide in Pure and Tablet Dosage Forms

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

PHARMA SCIENCE MONITOR

Research Article. *Corresponding author S.Ushasri

A NEW HPLC METHOD FOR THE QUANTIFICATION OF PANTOPRAZOLE IN PHARMACEUTICALS

International Journal of Pharma Research and Health Sciences. Available online at

of nm throughout the experimental work.

Journal of Chemical and Pharmaceutical Research

A novel analytical method development and validation for the estimation of simvastatin in bulk and pharmaceutical dosage forms by RP-HPLC

International Journal of Pharma and Bio Sciences V1(1)2010 UV- SPECTROPHOTOMETRIC DETERMINATION OF TENATOPRAZOLE FROM ITS BULK AND TABLETS

RP-HPLC Method for Simultaneous Estimation of Atenolol, Hydrochlorothiazide and Losarton in Tablet Dosage form

Received: ; Accepted:

SIMULTANEOUS ESTIMATION OF CILOSTAZOL AND ASPIRIN IN SYNTHETIC MIXTURE USING HPTLC METHOD

1. Introduction. Pharmazie 71 (2016) 683 ORIGINAL ARTICLES

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Simultaneous HPLC Determination of Methocarbamol, Paracetamol and Diclofenac Sodium

Analytical method development and validation of gabapentin in bulk and tablet dosage form by using UV spectroscopic method

ISSN: ; CODEN ECJHAO E-Journal of Chemistry , 9(1), 35-42

Development and validation of RP- HPLC method for determination of ticagrelor in pharmaceutical dosage formulation

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

4.1 MATERIALS 4.2 EQUIPMENTS

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Spectrophotometric Estimation of Glibenclamide and Alogliptin in Synthetic Mixture by Area under Curve Method

Impact factor: 3.958/ICV: 4.10 ISSN:

Simultaneous estimation and validation of bromhexine and cephalexin in bulk and pharmaceutical dosage form by RP-HPLC method

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

DEVELOPMENT AND VALIDATION OF A SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF DRONEDARONE IN BULK DRUG AND PHARMACEUTICAL FORMULATION

RP-HPLC Method for the Estimation of Nebivolol in Tablet Dosage Form

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3

Development and Validation of RP-HPLC Method for Quantitative estimation of Indapamide in Bulk and Pharmaceutical dosage forms

Development and validation of stability indicating reverse phase high performance liquid chromatography method for Timolol Maleate

Scholars Research Library

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

Method development and validation for the estimation of metronidazole in tablet dosage form by UV spectroscopy and derivative spectroscopy

Available online at Scholars Research Library

RP - HPLC METHOD FOR ESTIMATION OF PARACETAMOL FROM PHARMACEUTICAL FORMULATION FEBRINIL

STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF EPROSARTAN IN PURE AND PHARMACEUTICAL FORMULATION

Transcription:

International journal of Biomedical science ORIGIAL ARTICLE Liquid Chromatographic Methods for the Determination of Vildagliptin in the Presence of its Synthetic Intermediate and the Simultaneous Determination of Pioglitazone Hydrochloride and Metformin Hydrochloride Ramzia I. El-Bagary, Ehab F. Elkady, Bassam M. Ayoub Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt Abstract Two reversed-phase liquid chromatographic (RP-LC) methods are described for the determination of two binary mixtures of hypoglycemic agents. In the first method, vildagliptin (VDG) was determined in the presence of 3-amino-1-adamantanol (AAD), a synthetic intermediate and impurity of VDG. In the second method, pioglitazone hydrochloride (PGZ) and metformin hydrochloride (MET) were simultaneously determined in their binary mixture. Chromatographic separation in the two methods was achieved on a Symmetry Waters C18 column (150 mm 4.6 mm, 5 μm). In the first mixture, isocratic elution using a mobile phase of potassium dihydrogen phosphate buffer ph (4.6) - acetonitrile - methanol (30:50:20, v/v/v) at a flow rate of 1 ml min 1 with UV detection at 220 nm was performed. In the second method, isocratic elution based on potassium dihydrogen phosphate buffer ph (4.6) - acetonitrile (60:40, v/v) at a flow rate of 1 ml min 1 with UV detection at 210 nm was performed. Linearity, accuracy and precision were found to be acceptable over the concentration ranges of 5-200 μg ml 1, 0.5-3 μg ml 1 and 10-150 μg ml 1 for VDG, PGZ and MET, respectively. The optimized methods were validated and proved to be specific, robust, precise and accurate for the quality control of the drugs in their pharmaceutical preparations. (Int J Biomed Sci 2011; 7 (3): 201-208) Keywords: vildagliptin; pioglitazone hydrochloride; metformin hydrochloride; reversed-phase liquid chromatography; tablets ITRODUCTIO Vildagliptin (VDG), S-1-[-(3-hydroxy-1-adamantyl) glycyl]pyrrolidine-2-carbonitrile (Fig. 1a) is an oral hypoglycemic drug of the dipeptidyl peptidase 4 (DPP 4) Corresponding author: Bassam M. Ayoub, Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt. Tel: +20125104337; Fax: +20224148452L; E-mail: drbassamchemistry@hotmail.com. Received June 1, 2011; Accepted June 21, 2011 inhibitor class (1). DPP-4 inhibitors represent a new therapeutic approach to the treatment of type 2 diabetes (2). Literature survey reveals that only one spectrophotometric method was reported for the determination of VDG by the same authors of the present work (3). 3-Amino-1-adamantanol (AAD) (Fig. 1b) has been reported in the synthesis of vildagliptin (1), so it is expected to be an impurity of VDG. Due to lack of published liquid chromatographic methods for VDG, so the aim of the present work was to develop a reversed-phase liquid chromatographic (RP-LC) method that would be suitable for the determination of VDG either alone or in the presence of AAD as an expected impurity. www.ijbs.org Int J Biomed Sci vol. 7 no. 3 September 2011 201

HO H Pioglitazone hydrochloride (PGZ), ((RS) -5- (4- [2-(5-ethylpyridin-2-yl) ethoxy] benzyl)thiazolidine-2,4- dione (Fig. 1c) is one of the thiazolidinedione hypoglycemic agents. Metformin hydrochloride (MET),,-dimethylimidodicarbonimidic diamide (Fig. 1d) is a biguanide hypoglycemic drug that is regarded as the main compound in mixed therapies of oral hypoglycemics. Literature survey reveals that MET and PGZ have been simultaneously determined by a few methods, including spectrophotometry (4), HPLC (5, 6), LC/MS (7). Besides, some methods have been reported for determination of MET in mixtures including LC/MS/MS (8) and HPLC (9-12). This study presents the determination of PGZ and MET in binary mixture using HPLC-UV detection. In spite of the similarity of the applied mobile phase with a previous work (5), the minor changes in the mobile phase and the ph proved to shorten the time of the analysis with good peak shapes and good resolution between peaks of PGZ and MET. EXPERIMETAL (a) O (c) O Figure 1. Chemical structures of vildagliptin (a), vildagliptin synthetic intermediate (b), pioglitazone (c) and metformin (d). Instrumentation The HPLC system consisted of a Schimadzu LC-20 AT Liquid Chromatograph (Japan) using a Symmetry Waters C18 column (150 mm 4.6 mm, 5 μm) (Ireland). The system was equipped with a UV-visible detector (SPD- 20A, Japan) and an autosampler (SIL-20A, Schimadzu, Japan). An Elma S100 ultrasonic processor model KBK 4200 (Germany) was used for the degassing of the mobile phases. S O O H HO H 2 H (b) H (d) H H 2 Reagents and reference samples Pharmaceutical grade VDG, certified to contain 99.70% and Galvus tablets nominally containing 50 mg VDG per tablet (batch o. V6498) were kindly supplied from ovartis Europharm limited company (London, U.K.). Pharmaceutical grade PGZ, certified to contain 99.85% and Pioglumet tablets nominally containing 16.5 mg of PGZ and 850 mg of MET per tablet (batch o. 1001382) were kindly supplied by El Razy Pharma (Ismailia, Egypt). Pharmaceutical grade MET, certified to contain 99.79% was kindly supplied by Chemical Industries Development (CID) Co. (Giza, Egypt). Methanol (HiPerSolv for HPLC), Acetonitrile (HiPerSolv), potassium dihydrogen phosphate and orthophosphric acid (85%) were obtained from VWR Chemicals (Pool, England). Bi-distilled water was produced in-house (Aquatron Water Still, A4000D, UK). Membrane filters 0.45 µm from Teknokroma (Barcelona, Spain) were used. All other chemicals and reagents used were of analytical grade unless indicated otherwise. Standard stock solutions of each drug (1 mg ml -1 ) were prepared by dissolving 100 mg of the drug in methanol in a 100 ml volumetric flask and then completed to volume with methanol. Then required concentrations were prepared by serial dilutions with methanol of these stock solutions. Chromatographic conditions Chromatographic separation was achieved on a Symmetry Waters C18 column (150 mm 4.6 mm, 5 μm). In the first mixture (HPLC 1), isocratic elution using a mobile phase consisting of potassium dihydrogen phosphate buffer ph (4.6) - acetonitrile-methanol (30:50:20, v/v/v) with UV detection at 220 nm was performed. In the second mixture (HPLC 2), isocratic elution based on potassium dihydrogen phosphate buffer ph (4.6)-acetonitrile (60:40, v/v) with UV detection at 210 nm was performed. The buffer solution was filtered through 0.45µm membrane filter and degassed for 30 min in an ultrasonic bath prior to use. The mobile phase was pumped through the column at a flow rate of 1 ml min -1. Analyses were performed at ambient temperature and the injection volume was 25 µl. Samples preparation Twenty tablets of each pharmaceutical preparation were weighed. An accurately weighed amount of the finely powdered Galvus tablets equivalent to 100 mg of VDG was made up to 100 ml with methanol. An accurately weighed amount of the finely powdered Pioglumet tablets equivalent to (16.5 mg) PGZ and (850 mg) MET were 202 September 2011 Vol. 7 o. 3 Int J Biomed Sci www.ijbs.org

made up to 100 ml with methanol. The solutions were filtered followed by serial dilution to the required concentrations for each experiment. Procedure Linearity and repeatability For HPLC 1. Accurately measured aliquots of working standard solutions equivalent to 50-2000 µg VDG were transferred into a series of 10 ml volumetric flasks and then completed to volume with methanol. A volume of 25 µl of each solution was injected into the chromatograph. The chromatographic conditions mentioned under 2.3. including the mobile phase at a flow rate 1 ml min -1, detection at 220 nm and run time program for 10 min were adjusted. A calibration curve for VDG was obtained by plotting area under the peak (AUP) against concentration (C). The repeatability of the method was assessed by analyzing a mixture containing 100 µg ml -1 of VDG and 30 µg ml -1 of AAD (n=6). The precision (%R.S.D) was calculated (Table 1). For HPLC 2. Accurately measured aliquots of working standard solutions equivalent to 5-30 µg PGZ and 100-1500 µg MET were separately transferred into two series of 10mL volumetric flasks and then completed to volume with methanol. A volume of 25 µl of each solution was injected into the chromatograph. The chromatographic conditions mentioned under 2.3. including the mobile phase at a flow rate 1mL min -1, detection at 210 nm and run time program for 7.5 min were adjusted. A calibration curve for each compound was obtained by plotting area under the peak (AUP) against concentration (C). The repeatability of the method was assessed by analyzing a mixture containing 1.65 µg, 85 µg of PGZ and MET, respectively (n=6). The precision (%R.S.D) for each compound was calculated (Table 2). Assay of drugs in laboratory prepared mixtures and in pharmaceutical dosage forms For HPLC 1. The procedure mentioned under 2.5.1.1 was repeated using concentrations equivalent to 45-130 µg ml -1 VDG and 15-40 µg ml -1 AAD (10% to 30% of VDG, w/w). For the determination of the examined drug in Galvus tablets, the sample solution prepared under 2.4 was serially diluted to prepare solutions equivalent to 35-120 µg ml -1 of VDG and then injected in triplicates. The concentrations of the examined drug were calculated using calibration equation. For HPLC 2. The procedure mentioned under 2.5.1.2 was repeated using laboratory prepared mixtures equivalent to 1-2.8 µg ml -1 PGZ and 55-145 µg ml -1 MET. The concentration ratios of PGZ to MET in the mixtures were 1.5-2.5%, w/w. For the determination of the examined drugs in Pioglumet tablets, the sample solution prepared under 2.4 was serially diluted to prepare solutions equivalent to 0.49-2.43 and 25-125 µg ml -1 of PGZ and MET, respectively; and then injected in triplicates. The concentrations of the examined drugs were calculated by the calibration equations. RESULTS AD DISCUSSIO HPLC greatly reduces the analysis time and allows for the determination of many individual components in a mixture using one single procedure (13). o previous method was reported for the LC determination of VDG. Thus, the aim of this work was to develop a new, simple, accurate, reproducible and sensitive LC method for the determination of VDG either alone or in the presence of the intermediate of its synthesis (AAD) (HPLC 1). Alternatively, a previous work (5) described a reversedphase LC method for the simultaneous determination of Table 1. System suitability test for the proposed LC method (HPLC 1) for the determination of vildagliptin in binary mixture with its impurity Item VDG VDG impurities 1872 3136 R 2.92 T 1.1 1.01 RSD% of 6 injections Peak area 0.67 0.82 Retention time 0.18 0.23 Table 2. System suitability test for the proposed LC method (HPLC 2) for the simultaneous determination of pioglitazone and metformin in binary mixture Item PGZ MET 3413 1681 R 4.2 T 1.00 1.06 RSD% of 6 injections Peak area 0.85 0.73 Retention time 0.26 0.39 www.ijbs.org Int J Biomed Sci vol. 7 no. 3 September 2011 203

PGZ and MET. A Gemini C18 column (150 4.6 mm, 5 μ) was used with a mobile phase containing a mixture of acetonitrile and ammonium acetate buffer (ph 3) in the ratio of 42:58. The flow rate was 0.3 ml min -1 and effluents were monitored at 255 nm and eluted at 5.17 min (MET) and 8.1 min (PGZ). Calibration curves were plotted with a range from 0.5-50 μg ml -1 for MET and 0.3-30 μg ml -1 for PGZ. Upon investigation of such chromatographic conditions, one can first notice the flow rate (0.3 ml min -1 ) is low as the typical LC flow rate should be from 0.5 to 1 ml min -1 (14). Besides, ranges of the calibration are not suitable to the ranges of PGZ and MET in tablets. On the other hand, our method has the advantage of a shorter retention times with better sensitivity with a reasonable flow rate (1 ml min -1 ) and suitable linearity ranges for the two drugs. Methods development For HPLC 1. Various isocratic mobile phase systems at different ph values were attempted. Isocratic elution based on potassium dihydrogen phosphate buffer ph (4.6) - acetonitrile - methanol (30:50:20, v/v/v) was applied. Minimum retention times were obtained at a flow rate 1 ml min -1. The UV detector was operated at 220 nm where good detector sensitivity was achieved. The retention times were 6.2 and 8.2 min for VDG and AAD, respectively (Fig. 2). For HPLC 2. Various reversed-phase columns, isocratic mobile phase systems were attempted. Isocratic elution based on potassium dihydrogen phosphate buffer ph (4.6)-acetonitrile (60:40, %v/v) was applied. Minimum retention times were obtained at a flow rate 1mL min -1. The UV detector was operated at 210 nm where good detector sensitivity was achieved. The retention times were 5.90 and 4.07 min for PGZ and MET, respectively; as presented in Fig. 3. System suitability tests According to USP (15), system suitability tests are an integral part of liquid chromatographic methods in the course of optimizing the conditions of the proposed method. In the two proposed LC methods, system suitability tests are used to verify that resolution and reproducibility were adequate for analysis performed. Different parameters affecting the chromatographic separation were studied. The parameters of this test are column efficiency (number of theoretical plates), tailing of chromatographic peak, peak resolution factor, and repeatability as % R.S.D of peak areas for six injections and reproducibility of retention times. The results of these tests are listed in Tables 1-2. 0 50 100 150 200 0.0 2.5 5.0 7.5 10.0 0 100 200 300 400 0.0 2.5 5.0 7.5 Figure 2. A typical LC chromatogram of 25 µl injector of synthetic binary mixture of (a) vildagliptin (100 µg ml -1 ) and (b) vildagliptin impurity (30 µg ml -1 ). Figure 3. A typical LC chromatogram of 25 µl injector of synthetic binary mixture of (a) metformin (150 µg ml -1 ) and (b) pioglitazone hydrochloride (2.9 µg ml -1 ). 204 September 2011 Vol. 7 o. 3 Int J Biomed Sci www.ijbs.org

Methods validation Linearity. Linearity was studied for VDG, PGZ and MET. A linear relationship between area under the peak (AUP) and component concentration (C) was obtained. The regression equations were also computed. The linearity of the calibration curves were validated by the high value of correlation coefficients. The analytical data of the calibration curves including standard deviations for the slope and intercept (S b, S a ) are summarized in Tables 3-4. Accuracy. For HPLC 1 Accuracy of the results was calculated by % recovery of 5 different samples of VDG in laboratory prepared mixtures with AAD also by standard addition technique for Galvus tablets. The results obtained including the mean of the recovery and standard deviation are displayed in Table 3. For HPLC 2 Accuracy of the results was calculated by % recovery of 5 different samples of the laboratory prepared mixtures Table 3. Results obtained by LC method (HPLC 1) for the determination of vildagliptin in binary mixture with its impurity (3-amino-1-adamantanol) Item vildagliptin Retention time 6.3 Wavelength of detection 220 nm Range of linearity 5-200 μg.ml -1 Regression equation Area 10-5 = 0.5438 C μg/ml - 0.1127 Regression coefficient (r 2 ) 0.9998 LOD μg.ml -1 1.46 LOQ μg.ml -1 4.87 S b 3.5 10-3 S a 3.1 10-2 Confidence limit of the slope 0.5438 ± 1.69 10-2 Confidence limit of the intercept -0.1127 ± 3.94 10-4 Standard error of the estimation 0.176 Intraday % R.S.D 0.26-0.97 Interday % R.S.D 0.43-1.61 Drug in laboratory mixture 100.01 ± 1.75 Drug in dosage form 99.74 ± 1.03 Drug added 100.50 ± 1.13 of PGZ and MET and also by standard addition technique for Pioglumet tablet. The results obtained including the mean of the recovery and standard deviation are displayed in Table 4. Precision. For HPLC 1 The repeatability of the method was assessed by analyzing a mixture containing 100 µg ml -1 of VDG and 30 µg ml -1 of AAD (n=6). The values of the precision (% R.S.D) of repeatability and inter-day and intra-day precision (using 3 different concentrations in triplicates for three days) are displayed in Tables 1 & 3. For HPLC 2 The repeatability of the method was assessed by analyzing 1.65 µg ml -1 of PGZ and 85 µg ml -1 of MET (n=6). The values of the precision (% R.S.D) of repeatability and inter-day and intra-day precision (using 3 different concentrations in triplicates for three days) are displayed in Tables 2 & 4. Specificity. Specificity is the ability of the analytical method to measure the analyte response in the presence of interferences including degradation products and related substances. In the present work, specificity was checked by analyzing VDG with AAD and PGZ with MET in labo- 225 150 175 200 125 100 75 25 50 0 0.0 2.5 5.0 7.5 10.0 Figure 4. A typical LC chromatogram of 25 µl injector of 100 µg ml -1 Galvus sample solution www.ijbs.org Int J Biomed Sci vol. 7 no. 3 September 2011 205

Table 4. Results obtained by LC method (HPLC 2) for the simultaneous determination of pioglitazone and metformin in binary mixture Item Pioglitazone Metformin Retention time 5.90 4.07 Wavelength of detection 210 nm 210 nm Range of linearity 0.5-3 μg.ml -1 10-150 μg.ml -1 Regression equation Area 10-4 = 11.7832 C μg/ml - 0.0118 Area 10-6 = 0.0409 C μg/ml + 0.0418 Regression coefficient (r 2 ) 0.9997 0.9999 LOD μg.ml -1 0.06 1.95 LOQ μg.ml -1 0.17 5.91 S b 1.32 10-2 6.7 10-4 S a 2.26 10-2 6.5 10-2 Confidence limit of the slope 11.7832 ± 26.63 10-2 0.0409 ± 0.27 10-2 Confidence limit of the intercept -0.0118 ± 1.56 10-4 0.0418 ± 0.28 10-4 Standard error of the estimation 0.239 0.069 Intraday % R.S.D 0.26-0.59 0.13-0.43 Interday % R.S.D 0.37-1.75 0.62-1.26 Drug in laboratory mixture 99.99 ± 1.50 100.40 ± 1.60 Drug in dosage form 99.52 ± 1.38 100.73 ± 1.55 Drug added 100.13 ± 1.87 100.33 ± 1.33 200 Detector response (mau) 25 50 75 100 125 150 175 0 0.0 2.5 5.0 7.5 Time (min) Figure 5. A typical LC chromatogram of 25 µl injector of Pioglumet sample solution, (a) metformin (85 µg ml -1 ) and (b) pioglitazone hydrochloride (1.65 µg ml -1 ). ratory prepared mixtures. Good resolution and absence of interference between drugs being analyzed are shown in Fig. 2-3. Besides, the chromatograms of the pharmaceutical formulation samples were checked for the appearance of any extra peaks. o chromatographic interference from any of the excipients was found at the retention times of the examined drugs (Fig. 4 & 5). In addition, the chromatograms of the drugs in the samples solutions were found identical to the chromatograms received by the standard solutions at the wavelengths applied. Moreover, good results were obtained for the determination of the cited drugs in the two dosage forms, Tables 3-4. These results confirm the absence of interference from other materials in the pharmaceutical formulations and therefore confirm the specificity of the two proposed methods. Robustness. For HPLC 1 Robustness was performed by deliberately changing the chromatographic conditions. The most important parameter to be studied was the resolution factor between the two peaks of VDG and AAD. The flow rate of the mobile phase was changed from 1 ml min -1 to 0.8 ml min -1 and 1.2 ml 206 September 2011 Vol. 7 o. 3 Int J Biomed Sci www.ijbs.org

min -1, where resolution factors obtained were 2.92, 2.71 and 2.65 respectively. The organic strength was changed by ± 2% where resolution factors obtained were 2.92, 2.63 and 3.15 respectively. Finally, the value of ph of the phosphate buffer was varied from 4.6 to 4.5 and 4.7, where resolution factors obtained were 2.92, 2.54 and 3.22 respectively. As can be seen from these results, good values of the resolution factor were obtained for all these variations, indicating good robustness of the proposed LC method. For HPLC 2 The most important parameter to be studied was the resolution factor between the two peaks of PGZ and MET. The flow rate of the mobile phase was changed from 1 ml min -1 to 0.8 ml min -1 and 1.2 ml min -1, where resolution factors obtained were 4.20, 4.51 and 4.63 respectively. The organic strength was changed by % ± 2 where resolution factors obtained were 4.20, 3.86 and 3.91 respectively. Finally, a value of ph of the phosphate buffer was varied from 4.6 to 4.5 and 4.7, where resolution factors obtained were 4.20, 3.81 and 3.71 respectively. As can also be seen from these results, good values of the resolution factor were obtained for all these variations, indicating good robustness of the proposed LC method. Limit of detection and limit of quantification. Limit of detection (LOD) which represents the concentration of analyte at S/ ratio of 3 and limit of quantification (LOQ) at which S/ is 10 were determined experimentally for the proposed methods and results are given in Tables 3-4. Statistical analysis. Statistical analysis of the results obtained by the proposed methods and the reference methods for each drug were carried out by SPSS statistical package version 11. The significant difference between the reference methods and the described methods was tested by one way AOVA (F-test) at p=0.05 as shown in Tables 5-6. The test ascertained that there was no significant difference among the methods. COCLUSIO The proposed LC methods have the advantages of simplicity, precision, accuracy and convenience for the separation and quantization of VDG in combination with AAD, and also separation and simultaneous determination of PGZ in combination with MET. The two methods can be applied for the determination of the cited drugs in pharmaceutical dosage forms. The two methods were validated showing satisfactory data for all the method validation parameters tested. The developed methods can be conveniently used by quality control laboratories. Table 5. Statistical comparison between the results of the proposed LC method (HPLC 1) and the reference method for the determination of vildagliptin Statistical Term Reference Method b Proposed method Mean 100.01 100.008 S.D.± 0.99 1.75 S.E. ± 0.44 0.78 %RSD 0.99 1.75 n 5 5 V 0.98 3.06 t ( a 2.306) 0.002 F ( a 6.39) 0.32 a Figures in parentheses are the theoretical t and F values at (p=0.05); b Reference method: aliquots of standard solutions in distilled water containing 5-25 μg/ml VDG were measured at 210 nm using water as a blank (3). Table 6. Statistical comparison between the results of the LC method (HPLC 2) and the reference methods for the determination of pioglitazone and metformin Statistical Term Reference Method for PGZ b REFERECES HPLC method Reference Method for MET c HPLC method Mean 100.2 99.99 100.4 100.398 S.D.± 1.15 1.50 0.28 1.60 S.E. ± 0.51 0.67 0.13 0.72 %RSD 1.15 1.50 0.28 1.59 n 5 5 5 5 V 1.32 2.25 0.08 2.56 t ( a 2.306) 0.25 0.003 F ( a 6.39) 0.59 0.03 a Figures in parentheses are the theoretical t and F values at (p=0.05); b Reference method for the HPLC determination of pioglitazone (4); c Reference method for the spectrophotometric determination of metformin in the indian pharmacopeia (16). 1. Singh S, Manne, Pal M. Beilstein J. Org. Chem. 2008; 4: 20. 2. irogi R, Kandikere V, Mudigonda K, Komarneni P, et al. Biomed. Chromatogr. 2008; 22: 214. 3. El-bagary RI, Elkady EF, Ayoub B. Int. J. Biomed. Sci. 2011; 7: 55. 4. Shankar M, Modi V, Shah D, Bhatt K, et al. J. AOAC. Int. 2005; 88: 1167. 5. Lakshmi K, Rajesh T, Sharma S. Int. J. Pharm. Pharmac. Sci. 2009; 1: 162. 6. Lakshmi KS, Rajesh T, Sharma S, Lakshmi S. Der. Pharma. Chemica. 2009; 1: 238. www.ijbs.org Int J Biomed Sci vol. 7 no. 3 September 2011 207

7. Wang M, Miksa IR. J. Chromatogr. B. 2007; 856: 318. 8. Sengupta P, Bhaumik U, Ghosh A, Sarkar A, et al. Chromatographia. 2009; 69: 1243. 9. Xiong Y, Zhou H, Zhang Z. Fenxi-Shiyanshi. 2006; 25: 5. 10. Ali A, Duraidi I, Saket M, Abu-ameh E. J. AOAC. Int. 2009; 92: 119. 11. Porta V, Schramm S, Kano E, Koono E, et al. J. Pharm. Biomed. Anal. 2008; 46: 143. 12. Zhong L, Ling X, Sun H. Yaowu-Fenxi-Zazhi. 2008; 28: 1683. 13. Moffat A, Osselton M, Widdop B, Galichet L. Clarke s Analysis of Drugs and Poisons, 3rd edn. London: Pharmaceutical Press. 2004; 797, 1156. 14. Dong M. Handbook of pharmaceutical analysis by HPLC, 2005, Elsevier, 169. 15. United State Pharmacopoeia. 2007; 25 (1): 249-253. 16. The Indian Pharmacopoeia. 4th ed. ew Delhi: The Controller of Publications. 1996; 1: 469. 208 September 2011 Vol. 7 o. 3 Int J Biomed Sci www.ijbs.org